CRISPR疗法在人类肺芯片中将流感病毒水平削减了50%以上,显示出大范围流感治疗的前景。 CRISPR therapy cut flu virus levels by over 50% in human lung chips, showing promise for broad flu treatment.

哈佛的一项研究显示,基于CRISPR的治疗将人体肺部芯片(模仿人体肺组织的一种实验室模型)中的甲型流感病毒水平降低了50%以上。 A Harvard study shows CRISPR-based therapy reduced influenza A virus levels by over 50% in human lung chips, a lab model mimicking human lung tissue. 通过肺定向纳米粒子、切割病毒负荷和炎症提供治疗,同时尽量减少目标外影响。 The treatment, delivered via lung-targeting nanoparticles, slashed viral load and inflammation while minimizing off-target effects. 通过以受保护的病毒基因组区域为目标,这一方法可以对付多种流感菌株,为广泛频谱抗病毒提供潜力。 By targeting a conserved viral genome region, the approach may work against multiple flu strains, offering potential for broad-spectrum antivirals. 这项研究得到NIH和DARPA的支持,推动努力发展更快、更有效的流感治疗方法,克服动物模型和每年更新疫苗的局限性。 The research, supported by NIH and DARPA, advances efforts to develop faster, more effective flu treatments that overcome limitations of animal models and annual vaccine updates.